Press Releases March 27, 2026 08:07 AM

Inflection Point Acquisition Corp. VI Announces Pricing of $220 Million Initial Public Offering

Inflection Point Acquisition Corp. VI prices $220 million IPO to target disruptive growth sectors in North America and Europe

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
IPFXU

Inflection Point Acquisition Corp. VI, a special purpose acquisition company (SPAC), announced the pricing of its IPO, offering 22 million units at $10 each, expected to raise $220 million. The units will trade on Nasdaq under ticker IPFXU, with separate trading expected for shares and warrants under IPFX and IPFXW respectively. The company aims to merge with businesses in disruptive growth sectors primarily in North America and Europe but remains open to any industry or region.

Inflection Point Acquisition Corp. VI Announces Pricing of $220 Million Initial Public Offering
IPFXU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • The SPAC priced its IPO at $10 per unit, raising up to $220 million, with an option for underwriters to buy additional 3.3 million units.
  • Units will trade on Nasdaq under ticker IPFXU, with future separate listings for shares (IPFX) and warrants (IPFXW).
  • The company plans to seek a business combination primarily in disruptive growth sectors in North America or Europe but may pursue opportunities globally across industries.
  • Sectors impacted include technology and other disruptive growth industries, as well as financial markets related to SPAC IPOs and mergers.

Miami Beach, FL , March 27, 2026 (GLOBE NEWSWIRE) -- Inflection Point Acquisition Corp. VI (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, today announced the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Global Market, or Nasdaq, and trade under the ticker symbol “IPFXU” beginning March 27, 2026. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share (subject to adjustment pursuant to certain anti-dilution rights). Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “IPFX” and “IPFXW,” respectively.

The Company intends to pursue a business combination with a North American or European business in disruptive growth sectors, which complements the expertise of its management team, but may pursue an initial business combination in any industry, sector or geographic region. The Company is led by Chief Executive Officer Kevin Shannon, Chief Financial Officer Adam Saks, Chairman and Director Michael Blitzer, and Directors William Denkin, Christopher Kellen, Steven Tannenbaum, and Carolyn Trabuco.

The offering is expected to close on March 30, 2026, subject to customary closing conditions.

Cantor Fitzgerald & Co. is acting as book-running manager and Academy Securities, Inc. is acting as co-manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,300,000 units to cover over-allotments, if any.

A registration statement on Form S-1 (File No. 333-292443), as amended, relating to the securities was declared effective by the Securities and Exchange Commission (“SEC”) on March 26, 2026. The offering is being made only by means of a prospectus. When available, copies of the prospectus may be obtained from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York 10022; Email: prospectus@cantor.com or by accessing the SEC’s website, www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute "forward-looking statements," including with respect to the expected closing of the proposed initial public offering and search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

About Inflection Point Acquisition Corp. VI

Inflection Point Acquisition Corp. VI’s acquisition and value creation strategy is to identify, partner with and help grow North American and European businesses in disruptive growth sectors, which complements the expertise of its management team. However, the Company may pursue an initial business combination in any industry, sector or geographic region.

Contact
Kevin Shannon
Inflection Point Acquisition Corp. VI
info@inflectionpointacquisition.com


Risks

  • Uncertainty if the IPO will close as planned, and any delays or failure could adversely affect the company.
  • The SPAC has no current target business, so success depends on finding suitable acquisition opportunities within a limited timeframe.
  • Market conditions, regulatory changes, or adverse developments in the sectors targeted for acquisition could impact future business combination outcomes.

More from Press Releases

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems Jun 6, 2026 All In FutureTech Alliance Provides Strategic Updates: Hainan AIFA Digital Industrial Park, Silicon Photonics Compute Center Planning, and Cross-Border Optical Network Integration Jun 6, 2026 Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress Jun 6, 2026 InterPrivate Investment Partners V, Inc. Announces Closing of $201.25 Million Initial Public Offering Jun 5, 2026 Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 5, 2026